We serve Chemical Name:16,17-Bis(decyloxy)anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione CAS:71550-33-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:16,17-Bis(decyloxy)anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione
CAS.NO:71550-33-9
Synonyms:Anthra(9,1,2-cde)benzo(rst)pentaphene-5,10-dione, 16,17-bis(decyloxy)-;16,17-Bis(decyloxy)violanthrone;Anthra(9,1,2-cde)benzo(rst)pentaphene-5,10-dione,16,17-bis(decyloxy);16,17-Bis(decyloxy)anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione;Anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione, 16,17-bis(decyloxy)-;EINECS 275-606-3
Molecular Formula:C54H56O4
Molecular Weight:769.020
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.2±0.1 g/cm3
Index of Refraction:1.666
PSA:52.60000
Exact Mass:768.417847
LogP:18.52
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Anthra(9,1,2-cde)benzo(rst)pentaphene-5,10-dione, 16,17-bis(decyloxy)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 275-606-3 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,16,17-Bis(decyloxy)anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione Use and application,Anthra(9,1,2-cde)benzo(rst)pentaphene-5,10-dione, 16,17-bis(decyloxy)- technical grade,usp/ep/jp grade.
Related News: Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers. 16,17-Bis(decyloxy)anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione manufacturer Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule. 16,17-Bis(decyloxy)anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione supplier Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule. 16,17-Bis(decyloxy)anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione vendor From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 16,17-Bis(decyloxy)anthra[9,1,2-cde]benzo[rst]pentaphene-5,10-dione factory Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers.